Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts
BALA CYNWYD, Pa., June 28, 2022 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that biomarker studies that have identified genes that are differentially expressed between healthy individuals and those with Friedreich’s ataxia will be featured in an oral presentation at the upcoming Gordon Research Conference on Mitochondria and Chloroplasts during the session on “Organelle Biology Translated into Medicine and Agriculture.” The conference will take place July 17 – 22, 2022 at Mount Snow in West Dover, Vermont.
Details on the presentation are shown below.
| Presentation Title: | Identification of Differentially Expressed Genes in Friedreich’s Ataxia Patients |
| Presenting Author: | David Bettoun, Ph.D., Vice President of Discovery and Non-clinical R&D, Larimar Therapeutics |
| Presentation Date: | July 21, 2022 |
| Presentation Time: | 8:40 PM ET |
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich’s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
